Table 34.
Country | Gentamicin | Co‐amoxiclav | Ciprofloxacin | Erythromycin | Tetracyclines | |||||
---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
Austria | 37 | 2.7 | – | – | 37 | 81.1 | 37 | 2.7 | 37 | 67.6 |
Cyprus | – | – | – | – | 7 | NA | 7 | NA | 7 | NA |
Estonia | – | – | – | – | 19 | 89.5 | 19 | 63.2 | 19 | 73.7 |
Finlanda | – | – | – | – | 272 | 84.6 | 263 | 22.8 | 143 | 69.2 |
Franceb | 797 | 1.6 | 881 | 0.5 | 882 | 67.0 | 881 | 6.4 | 851 | 77.3 |
Italy | 9 | NA | – | – | 11 | 100 | 11 | 27.3 | 11 | 90.9 |
Lithuaniab | – | – | – | – | 41 | 92.7 | 41 | 17.1 | 40 | 80.0 |
Luxembourg | – | – | 53 | 26.4 | 53 | 84.9 | 53 | 13.2 | 53 | 81.1 |
Malta | 6 | NA | 6 | NA | 61 | 70.5 | 61 | 9.8 | 7 | NA |
Netherlandsb | – | – | – | – | 164 | 65.2 | 146 | 9.6 | 107 | 65.4 |
Portugal | 34 | 0 | – | – | 34 | 100 | 34 | 50.0 | 34 | 91.2 |
Romania | 16 | 0 | 16 | 0 | 16 | 31.3 | 16 | 0 | 16 | 18.8 |
Slovakiab | 1 | NA | 24 | 12.5 | 53 | 60.4 | 64 | 4.7 | 66 | 37.9 |
Slovenia | – | – | – | – | 130 | 66.2 | 130 | 2.3 | 130 | 47.7 |
Spain | 38 | 5.3 | – | – | 38 | 84.2 | 38 | 23.7 | 38 | 84.2 |
United Kingdomb | – | – | – | – | 747 | 44.3 | 678 | 11.1 | 360 | 35.6 |
Total (16 MSs) | 938 | 1.7 | 980 | 2.7 | 2,565 | 63.8 | 2,479 | 11.0 | 1,919 | 64.8 |
Icelandb | – | – | – | – | 1 | NA | 1 | NA | – | – |
Norway | 10 | 0 | – | – | 10 | 80.0 | 10 | 10.0 | 10 | 90.0 |
N: number of isolates tested; % Res: percentage of resistant isolates (either non‐wild type by ECOFFs or clinically non‐susceptible by combining resistant and intermediate categories); –: no data reported; NA: not applicable (if less than 10 isolates were tested, the percentage of resistance was not calculated).
Travel‐associated cases, accounting for 65% of Campylobacter infections in Finland in 2016, could not be excluded from the Finnish AST data.
Data interpreted with clinical breakpoints.